Differential agonist regulation of the human kappa-opioid receptor

被引:0
|
作者
Blake, AD [1 ]
Bot, G [1 ]
Li, SX [1 ]
Freeman, JC [1 ]
Reisine, T [1 ]
机构
[1] UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104
关键词
kappa-opioid receptor; desensitization; down-regulation; opioid tolerance;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Opiates are potent analgesics used clinically in the treatment of pain. A significant drawback to the chronic use and clinical effectiveness of opiates is the development of tolerance. To investigate the cellular mechanisms of tolerance, the cloned human kappa-opioid receptor was stably expressed in human embryonic kidney (HEK 293) cells, and the effects of opioid agonist treatment were examined. The receptor-expressing cells showed specific high-affinity membrane binding for a kappa-selective opioid, H-3-labeled (+)-(5 alpha,7 alpha,8 beta)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4,5]dec-8-yl]benzeneacetamide ([H-3]U69,593), and a nonselective opioid antagonist, [H-3]diprenorphine. Pretreatment with pertussis toxin or guanosine 5'-O-(3-thiotriphosphate) reduced [H-3]69,593 binding, indicating that the human kappa receptor coupled to G proteins of the G(i) or G(o) families in HEK 293 cells. The receptor-mediated inhibition of adenylyl cyclase was abolished by pertussis toxin pretreatment and was blocked by a kappa-selective antagonist, norbinal-torphimine. A 3-h pretreatment with a kappa-selective agonist, (+/-)-trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide (U50,488), caused receptor down-regulation, whereas no receptor down-regulation was found after levorphanol pretreatment. U50,488 or dynorphin A(1-17) pretreatments (3 h) desensitized the ability of U50,488 or dynorphin A(1-17) to inhibit cyclic AMP accumulation, as evidenced by a decrease in functional potency. Also, U50,488 pretreatment desensitized the ability of levorphanol to inhibit forskolin-stimulated cyclic AMP accumulation. In contrast, pretreatment of cells with either levorphanol or a potent nonselective opioid, etorphine, resulted in no apparent receptor desensitization. Taken together, these results demonstrate that the human kappa receptor is differentially regulated by selective and nonselective opioid agonists, with selective agonists able to desensitize the receptor.
引用
收藏
页码:1846 / 1852
页数:7
相关论文
共 50 条
  • [1] HUMAN LEUMORPHIN IS A POTENT, KAPPA-OPIOID RECEPTOR AGONIST
    SUDA, M
    NAKAO, K
    YOSHIMASA, T
    SAKAMOTO, M
    MORII, N
    IKEDA, Y
    YANAIHARA, C
    YANAIHARA, N
    NUMA, S
    IMURA, H
    [J]. NEUROSCIENCE LETTERS, 1984, 50 (1-3) : 49 - 52
  • [2] Agonist-induced phosphorylation of the kappa-opioid receptor
    Appleyard, SM
    Patterson, TA
    Jin, WZ
    Chavkin, C
    [J]. JOURNAL OF NEUROCHEMISTRY, 1997, 69 (06) : 2405 - 2412
  • [3] Antipruritic effect of kappa-opioid receptor agonist in mice
    Niida, Takahiro
    Mizoguchi, Hirokazu
    Watanabe, Chizuko
    Yonezawa, Akihiko
    Nagase, Hiroshi
    Sakurada, Shinobu
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 124 : 189P - 189P
  • [4] PD117302 - A SELECTIVE AGONIST FOR THE KAPPA-OPIOID RECEPTOR
    CLARK, CR
    BIRCHMORE, B
    SHARIF, NA
    HUNTER, JC
    HILL, RG
    HUGHES, J
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1988, 93 (03) : 618 - 626
  • [5] CHOLECYSTOKININ-A RECEPTOR LIGANDS BASED ON THE KAPPA-OPIOID AGONIST TIFLUADOM
    BOCK, MG
    DIPARDO, RM
    EVANS, BE
    RITTLE, KE
    WHITTER, WL
    VEBER, DF
    FREIDINGER, RM
    CHANG, RSL
    CHEN, TB
    LOTTI, VJ
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (01) : 450 - 455
  • [6] PHARMACOLOGICAL PROPERTIES OF NALFURAFINE, A NOVEL ANTIPRURITIC AND KAPPA-OPIOID RECEPTOR AGONIST
    Nakao, Kaoru
    [J]. ACTA DERMATO-VENEREOLOGICA, 2009, 89 (06) : 706 - 706
  • [7] STRUCTURAL AND AGONIST BINDING-SITE MODEL OF THE KAPPA-OPIOID RECEPTOR
    METZGER, TG
    FERGUSON, DM
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 210 : 16 - COMP
  • [8] Kappa-opioid receptor ligands
    Husbands, SM
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (12) : 1725 - 1741
  • [9] A newly developed kappa-opioid receptor agonist ameliorates ongoing inflammation
    Sucker, N.
    Soeberdt, M.
    Abels, C.
    Luger, T.
    Loser, K.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 : S72 - S72
  • [10] CI-977, A NOVEL AND SELECTIVE AGONIST FOR THE KAPPA-OPIOID RECEPTOR
    HUNTER, JC
    LEIGHTON, GE
    MEECHAM, KG
    BOYLE, SJ
    HORWELL, DC
    REES, DC
    HUGHES, J
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1990, 101 (01) : 183 - 189